From - Mon Dec 17 16:00:31 2007 Received: from mail.mdanderson.org (mail.mdanderson.org [143.111.251.38]) by wotan.mdacc.tmc.edu (8.13.6/) with ESMTP id lBEIO91Y409067 for ; Fri, 14 Dec 2007 12:24:09 -0600 (CST) Received: from ([171.66.124.133]) by mdairnmail2.mdacc.tmc.edu with ESMTP id KP-BRCRK.133827971; Fri, 14 Dec 2007 12:21:58 -0600 Received: from madcap.stanford.edu (madcap.Stanford.EDU [171.66.121.176]) by marz.stanford.edu (Postfix) with ESMTP id 36B832DEBE6; Fri, 14 Dec 2007 10:21:58 -0800 (PST) Received: from madcap.stanford.edu (localhost [127.0.0.1]) by madcap.stanford.edu (Postfix) with ESMTP id 9B006C44; Fri, 14 Dec 2007 10:21:58 -0800 (PST) Message-ID: <1157637.1197656518623.JavaMail.benchpress@highwire.org> From: gunne@asco.org To: Keith A Baggerly , crboucha@mdanderson.org Subject: Decision/Correspondence - JCO/2007/151985 Mime-Version: 1.0 Content-Type: text/plain; charset=ISO8859-1 Content-Transfer-Encoding: quoted-printable Date: Fri, 14 Dec 2007 10:21:58 -0800 (PST) X-esp: ESP<0>= SHA:<0> UHA:<8> ISC:<0> BAYES:<-1> SenderID:<0> DKIM:<0> TS:<-7> SIG: TRU_test01: <0> TRU_lotto_spam: <0> TRU_embedded_image_spam: <0> TRU_urllinks: <0> TRU_freehosting: <0> TRU_medical_spam: <0> URL Real-Time Signatures: <0> TRU_test04: <0> TRU_stock_spam: <0> TRU_legal_spam: <0> TRU_scam_spam: <0> TRU_html_image_spam: <0> TRU_adult_spam: <0> TRU_test03: <0> TRU_charsets: <0> TRU_misc_spam: <0> TRU_phish_spam: <0> TRU_profanity_spam: <0> TRU_marketing_spam: <0> TRU_money_spam: <0> TRU_test00: <0> TRU_watch_spam: <0> TRU_test05: <0> X-Mozilla-Status: 9001 X-Mozilla-Status2: 00000000 X-UIDL: mc~!!]>%#!?L%"!h)m!! Dear Dr. Baggerly: We have reviewed your correspondence, titled =93Pharmacogenomic Strategies = May=20 Not Provide a Rational Approach to the Treatment of Cisplatin-Resistant=20 Patients with Advanced Lung Cancer.=94 I regret to inform you that we cann= ot=20 accept your correspondence for publication. Thank you for giving us the opportunity to consider your correspondence for= the=20 Journal of Clinical Oncology. Sincerely, Daniel G. Haller, MD Editor-in-Chief Journal of Clinical Oncology RC